Securities Code: 301290
Securities Abbreviation: Dongxing Medical
Announcement Number: 2026-026
Jiangsu Dongxing Smart Medical Technology Co., Ltd. (hereinafter referred to as "the Company" or "the Listed Company") disclosed the "Draft Major Asset Purchase Report of Jiangsu Dongxing Smart Medical Technology Co., Ltd." (hereinafter referred to as "this transaction draft") on May 12, 2026. The Company intends to purchase 90% of the equity of Wuhan Yijiaobao Biological Materials Co., Ltd. (hereinafter referred to as "Wuhan Yijiaobao" or "the Target Company") for cash (hereinafter referred to as "this transaction"). The "Major Risk Warning" and "Chapter 11 Risk Factor Analysis" in this transaction draft detail the potential risk factors and other procedures that need to be fulfilled, and investors are advised to pay attention to investment risks.